Is lung involvement a favorable prognostic factor for pancreatic ductal adenocarcinoma with synchronous liver metastases?—A propensity score analysis
(2023) In Expert Review of Gastroenterology and Hepatology- Abstract
- Background
For advanced pancreatic cancer, pulmonary metastases (PM) have been considered favorable factors compared to metastases of other sites, but it remains unknown whether the prognosis of patients with synchronous liver and lung metastases is better than that of non-PM.
Methods
Data was derived from a two-decade cohort and included 932 cases of pancreatic adenocarcinoma with synchronous liver metastases (PACLM). Propensity score matching (PSM) was applied to balance 360 selected cases, grouped into PM (n = 90) and non-PM (n = 270). Overall survival (OS) and survival-related factors were analyzed.
Results
In PSM-adjusted data, the median OS was 7.3 and 5.8 months, for PM and non-PM, respectively (p =... (More) - Background
For advanced pancreatic cancer, pulmonary metastases (PM) have been considered favorable factors compared to metastases of other sites, but it remains unknown whether the prognosis of patients with synchronous liver and lung metastases is better than that of non-PM.
Methods
Data was derived from a two-decade cohort and included 932 cases of pancreatic adenocarcinoma with synchronous liver metastases (PACLM). Propensity score matching (PSM) was applied to balance 360 selected cases, grouped into PM (n = 90) and non-PM (n = 270). Overall survival (OS) and survival-related factors were analyzed.
Results
In PSM-adjusted data, the median OS was 7.3 and 5.8 months, for PM and non-PM, respectively (p = 0.16). Multivariate analysis revealed that male gender, poor performance status, higher hepatic tumor burden, ascites, elevated carbohydrate antigen 19–9, and lactate dehydrogenase were factors of poor survival (p < 0.05). Chemotherapy was the only independent significant factor of favorable prognosis (p < 0.05).
Conclusion
Although lung involvement was indicated to be a favorable prognostic factor for patients with PACLM in the whole cohort, PM were not associated with better survivals in the subset of cases subjected to PSM adjustment. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/29e6358a-3fda-4b7e-a1b7-9f4682a542fa
- author
- Ouyang, Huaqiang LU ; Ma, Weidong ; Jiang, Xiangli ; Sandström Gerdtsson, Anna LU ; Liu, Donglin LU and Pan, Zhanyu
- organization
- publishing date
- 2023-02-23
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Expert Review of Gastroenterology and Hepatology
- publisher
- Expert Reviews Ltd.
- external identifiers
-
- pmid:36803208
- scopus:85149295012
- ISSN
- 1747-4124
- DOI
- 10.1080/17474124.2023.2183497
- language
- English
- LU publication?
- yes
- id
- 29e6358a-3fda-4b7e-a1b7-9f4682a542fa
- date added to LUP
- 2023-02-24 09:39:15
- date last changed
- 2023-03-30 04:11:46
@article{29e6358a-3fda-4b7e-a1b7-9f4682a542fa, abstract = {{Background<br/>For advanced pancreatic cancer, pulmonary metastases (PM) have been considered favorable factors compared to metastases of other sites, but it remains unknown whether the prognosis of patients with synchronous liver and lung metastases is better than that of non-PM.<br/><br/>Methods<br/>Data was derived from a two-decade cohort and included 932 cases of pancreatic adenocarcinoma with synchronous liver metastases (PACLM). Propensity score matching (PSM) was applied to balance 360 selected cases, grouped into PM (n = 90) and non-PM (n = 270). Overall survival (OS) and survival-related factors were analyzed.<br/><br/>Results<br/>In PSM-adjusted data, the median OS was 7.3 and 5.8 months, for PM and non-PM, respectively (p = 0.16). Multivariate analysis revealed that male gender, poor performance status, higher hepatic tumor burden, ascites, elevated carbohydrate antigen 19–9, and lactate dehydrogenase were factors of poor survival (p < 0.05). Chemotherapy was the only independent significant factor of favorable prognosis (p < 0.05).<br/><br/>Conclusion<br/>Although lung involvement was indicated to be a favorable prognostic factor for patients with PACLM in the whole cohort, PM were not associated with better survivals in the subset of cases subjected to PSM adjustment.}}, author = {{Ouyang, Huaqiang and Ma, Weidong and Jiang, Xiangli and Sandström Gerdtsson, Anna and Liu, Donglin and Pan, Zhanyu}}, issn = {{1747-4124}}, language = {{eng}}, month = {{02}}, publisher = {{Expert Reviews Ltd.}}, series = {{Expert Review of Gastroenterology and Hepatology}}, title = {{Is lung involvement a favorable prognostic factor for pancreatic ductal adenocarcinoma with synchronous liver metastases?—A propensity score analysis}}, url = {{http://dx.doi.org/10.1080/17474124.2023.2183497}}, doi = {{10.1080/17474124.2023.2183497}}, year = {{2023}}, }